English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Breast cancer is one of the most public and fatal malignancy worldwide. One of the main cytokines playing a role in breast cancer progression is TGF1. In this study we aimed to determine the clinical significance of the serum TGFβ1 levels in breast cancer patients by comparing the levels of TGFβ1 in breast cancer patients and in control females, assessment of the levels of TGFβ1 in diagnosed breast cancer patients before and after treatment and correlating between the levels of TGFβ1 in breast cancer patients with the laboratory and radiological findings. Our study was carried out on 35 breast cancer female cases and 20 females free from breast cancer with matched age as a control group. Higher levels of TGFβ1 are detected among breast cancer females than the control group with statistically significant difference between TGFβ1 after treatment as regarding to metastasis occurrence. This indicates that the circulating TGFβ1 after treatment may be used as a prognostic marker in breast cancer patients. Also, our study shows that there were statistically significant predictors affecting metastasis rate among studied cases when both ER was positive and TGFβ1 after treatment was more than median. K e y w o r d s

Transforming Growth Factor Beta 1 (TGFβ1) as an Immunological Marker in Breast Cancer Patients